BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Elvitegravir: Additional Phase III data

Additional data from the double-blind, international Phase III Study GS-US-183-0145 trial in 702 treatment-experienced patients showed that once-daily oral elvitegravir was non-inferior to twice-daily 400 mg Isentress raltegravir in the proportion of patients who achieved and maintained HIV RNA levels <50 copies/mL at week 96 (48% vs. 45%, 95% CI for the difference: -4.6%, 9.9%). Additionally, rates of discontinuation due to adverse events were comparable between treatment arms. In March, Gilead reported that elvitegravir met the primary endpoint of non-inferiority to Isentress in the proportion...

Read the full 415 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >